After ODAC: The State Of Accelerated Approval At The US FDA

 
• By Michael McCaughan
  
Will Pazdur be able to tell his fellow oncologists that the state of accelerated approval is strong?

More from US FDA Performance Tracker

More from Regulatory Trackers